Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 5/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3728268 | 1.00 | MAPT (0.36) | MAPTPOLBALPLMAPK1NPC1 | |
| SCHEMBL954495 | 0.81 | CNR1 (0.42) | MAPTPOLBALPLALDH1A1CNR1 | |
| SCHEMBL3944166 | 0.72 | GAA (0.50) | MAPTPOLBCNR1 | |
| SCHEMBL16310085 | 0.69 | TUBB (0.43) | MAPTALPLALDH1A1CNR1GSK3B | |
| SCHEMBL953237 | 0.67 | ALPL (0.52) | ALPLNPC1ALDH1A1 | |
| SCHEMBL955251 | 0.66 | MAPT (0.52) | MAPTPOLBALPLMAPK1NPC1 | |
| SCHEMBL7665056 | 0.63 | KDM4E (0.54) | NPC1ALDH1A1ALKBH5 | |
| SCHEMBL954496 | 0.63 | THRB (0.36) | MAPTALPLCNR1PTGDR2DPP4 | |
| SCHEMBL955230 | 0.61 | ACE2 (0.48) | MAPTALDH1A1CNR1 | |
| SCHEMBL4338636 | 0.59 | HSD11B1 (0.47) | POLBALPLDPP4DPP8HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825140-B2 | Utilizing such as 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide against cancer growth | ASTEX THERAPEUTICS, LTD. (GB) | 2010-11-02 | — | — | US | disclosed |
| US-20080200509-A1 | Utilizing such as 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide against cancer growth | ASTEX THERAPEUTICS, LTD. (GB) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200509-A1 | Utilizing such as 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide against cancer growth | CDK3, CDK4, CDK1 | MAPT 2960/4885POLB 1485/4885ALPL 4716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.